KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Operating Expenses (2016 - 2026)

Bristol Myers Squibb has reported Operating Expenses over the past 18 years, most recently at $8.2 billion for Q1 2026.

  • Quarterly Operating Expenses changed 0.24% to $8.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $38.9 billion through Mar 2026, down 6.36% year-over-year, with the annual reading at $38.9 billion for FY2025, 31.43% down from the prior year.
  • Operating Expenses was $8.2 billion for Q1 2026 at Bristol Myers Squibb, down from $11.0 billion in the prior quarter.
  • Over five years, Operating Expenses peaked at $23.4 billion in Q1 2024 and troughed at $8.2 billion in Q1 2025.
  • The 5-year median for Operating Expenses is $9.8 billion (2023), against an average of $10.5 billion.
  • Year-over-year, Operating Expenses soared 172.92% in 2024 and then plummeted 64.8% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $9.5 billion in 2022, then increased by 2.68% to $9.8 billion in 2023, then grew by 24.12% to $12.2 billion in 2024, then decreased by 9.33% to $11.0 billion in 2025, then decreased by 25.22% to $8.2 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Operating Expenses are $8.2 billion (Q1 2026), $11.0 billion (Q4 2025), and $9.1 billion (Q3 2025).